Meta-analysis of the efficacy and safety of intranasal corticosteroids. Clinical advantage andunresolved problems



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

References

  1. Compalati E., Penagos M., Henley K., Canonica G.W. Allergy Prevalence Survey by the World Allergy Organization. Allergy Clin. Immunol. Int. J. World Allergy Org. 2007, v. 19, p. 82-90.
  2. Asher M.I. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006, v. 368, p.733-743.
  3. Prenner B.M., Schenkel E. Allergic rhinitis: treatment based on patient profiles. Am. J. Med. 2006, v. 119, p. 230-237.
  4. van Drunen C., Meltzer E.O., Bachert C. et al. Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate. Allergy. 2005, v. 60, p. S5-S19.
  5. Bousquet J. Allergic rhinitis and its impact on asthma (ARIA). Clin. Exp. All. Rev. 2003, v. 3, p. 43-45.
  6. Brozek J.L., Baena-Cagnani C., Bonini S. et al. Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2007 update. Allergy. 2008, v. 63, p. 38-46.
  7. Canonica G.W., Tarantini F., Compalati E., Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, doubleblind, controlled trials. Allergy. 2007, v. 62, p. 359-366.
  8. Scadding G.K., Durham S.R., Mirakian R. et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin. Exp. Allergy. 2008, v. 38, p. 19-42.
  9. Bousquet J., van Cauwenberge P. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 2001, v. 108, S146-S150.
  10. Plaut M., Valentine M.D. Allergic rhinitis.N. Engl. J. Med. 2005, v. 353, p. 1934-1944.
  11. van Cauwenberge P. Consensus statement* on the treatment of allergic rhinitis. Allergy. 2000, v. 55, p. 116-134.
  12. Lundblad L., Sipilaе P., Farstad T., Drozdziewicz D. Mometasone furoate nasal spray in the treatment of perennial non-allergic rhinitis: a nordic, multicenter, randomized, double-blind, placebocontrolled study. Acta Otolaryngol. 2001, v. 121, p. 505-509.
  13. Stjarne P., Blomgren K., Caye-Thomasen P. , Salo S., Sode strom T. The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo-controlled study. Acta Otolaryngol. 2006, v. 126, p. 606-612.
  14. Small C.B., Hernandez J., Reyes A. et al. Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J. Allergy Clin. Immunol. 2005, v. 116, p. 1275-1281.
  15. Berlucchi M., Salsi D., Valetti L., Parrinello G., Nicolai P. The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study. Pediatrics. 2007, v. 119, p. 1392-1397.
  16. Meltzer E.O., Bachert C., Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J. Allergy Clin. Immunol. 2005, v. 116, p. 1289-1295.
  17. Barnes M.L., Biallosterski B.T., Fujihara S. et al. Effects of intranasal corticosteroid on nasal adenosine monophosphate challenge in persistent allergic rhinitis. Allergy. 2006, v. 61, p. 1319-1325.
  18. Hebert J.R., Nolop K., Lutsky B.N. Oncedaily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy. 1996, v. 51, p. 569-576.
  19. Meltzer E.O., Jalowayski A.A., Orgel H.A., Harris A.G. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J. Allergy Clin. Immunol. 1998, v. 102, p. 39-49.
  20. Graft D., Aaronson D., Chervinsky P. et al. A placebo- and active controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J. Allergy Clin. Immunol. 1996, v. 98, p. 724-731.
  21. Mandl M., Nolop K., Lutsky B.N. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group. Ann. Allergy Asthma Immunol. 1997, v. 79, p. 370-378.
  22. Zitt M., Kosoglou T. , Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf. 2007, v. 30, p. 317-326.
  23. Cutler D.L., Banfield C., Affrime M.B. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol. 2006, v. 19, p. 146-153.
  24. Meltzer E.O., Berger W.E., Berkowitz R.B. et al. A doseranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 1999, v. 104, p. 107-114.
  25. Brannan M.D., Seiberling M., Cutler D.L. et al. Lack of systemic activity with intranasal mometasone furoate. J. Allergy Clin. Immunol. 1996, v. 97, p. 198-204.
  26. Schenkel E., Skoner D., Bronsky E. et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000, v. 105, p. E22.
  27. Minshall E., Ghaffar O., Cameron L. et al. Assessment by nasal biopsy of long-time use of mometasone furoate aque-ous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg. 1998, v. 118, p. 648-654.
  28. Moher D., Cook D.J., Eastwood S. et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. Quality of reporting meta-analysis. Lancet. 1999, v. 354, p. 1896-1900.
  29. Higgins J.P.T., Green S. (editors). Cochrane handbook for systematic reviews of interventions version 5.0.0. [Updated February 2008]. The Cochrane Collaboration, 2008. Available from <http://www.cochranehandbook>. org.
  30. Robinson K.A., Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int. J. Epidemiol. 2002, v. 31, p. 150-153.
  31. Dawson B. Research questions about one group. In: Dawson B., editor. Basic & clinical biostatistics, 4th edn. New York: McGraw-Hill Medical. 2004, p. 118.
  32. Viera A.J., Garrett J.M. Understanding interobserver agreement: the kappa statistic. Fam. Med. 2005, v. 37, p. 360-363.
  33. Jadad A.R., Moore R.A., Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials. 1996, v. 17, p. 1-12.
  34. Moher D., Cook D.J., Jadad A.R. et al. Assessing the quality of randomized controlled trials: implications for the conduct of meta-analyses. Health Technol. Assess. 1999, v. 3, No. 12.
  35. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986, v. 1, p. 307-310.
  36. MedCalc for Windows, Version 8.1.1 [Computer program]. Mariakerke: MedCalc Software, 2006.
  37. Plot Digitizer 2.4.1 Program [Computer program]. Kansas, 2003.
  38. Spector S.L., Nicklas R.A., Chapman J.A. et al. Symptom severity assessment of allergic rhinitis: part 1. Ann. Allergy Asthma Immunol. 2003, v. 91, p. 105-114.
  39. Deeks J.J., Altman D., Bradburn M.J. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M., Davey Smith G., Altman D.G., editors. Systematic reviews in health care. London: BMJ Publishing. 2001, v. 285-312.
  40. Egger M., Smith G.D., Phillips A.N. Metaanalysis: principles and procedures. BMJ. 1997, v. 315, p. 1533-1537.
  41. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ. 2003, v. 327, p. 557-560.
  42. Sutton A.J., Higgins J.P. Recent developments in meta-analysis. Stat Med. 2008, v. 27, p. 625-650.
  43. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials. 1986, v. 7, p. 177-188.
  44. DerSimonian R., Kacker R. Randomeffects model for meta-analysis of clinical trials: an update. Contemp. Clin. Trials. 2007, v. 28, p. 105-114.
  45. Wang M.C., Bushman B.J. Using the normal quantile plot to explore metaanalytic data sets. Psychol. Methods. 1998, v. 3, p. 46-54.
  46. Penagos M., Passalacqua G., Compalati E. et al. Meta-analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008, v. 133, p. 599-609.
  47. RevMan Analyses Version 5.0 for Windows [Computer program]. Oxford: The Cochrane Collaboration, 2008.
  48. SPSS Version 14.0 for Windows [Computer program]. Chicago, IL: SPSS Inc, 2007.
  49. Bronsky E.A., Aaronson D.W., Berkowitz R.B. et al. Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 1997, v. 79, p. 51-56.
  50. Bende M., Carrillo T., Voґ na I., da Castel-Branco M.G., Arheden L. A randomized comparison of the effects of budes-onide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 2002, v. 88, p. 617-623.
  51. Drouin M., Yang W.H., Bertrand B. et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann. Allergy Asthma Immunol. 1996, v. 77, p. 153-160.
  52. Berkowitz R.B., Bernstein D.I., LaForce C. et al. Onset of action of mometasone furoate nasal spray (NASONEX) in seasonal allergic rhinitis. Allergy. 1999, v. 54, p. 64-69.
  53. Stuck B.A., Blum A., Hagner A.E. et al. Mometasone furoate nasal spray improves olfactory performance in seasonal allergic rhinitis. Allergy. 2003, v. 58, p. 1195.
  54. Gawchik S., Goldstein S., Prenner B., John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann. Allergy Asthma Immunol. 2003, v. 90, p. 416-421.
  55. Ciprandi G., Tosca M.A., Passalacqua G., Canonica G.W. Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. Ann. Allergy Asthma Immunol. 2001, v. 86, p. 433-438.
  56. Frieri M., Therattil J., Chavarria V. et al.Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 1998, v. 81, p. 431-437.
  57. Patel P. , D Andrea C., Sacks H.J. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am. J. Rhinol. 2007, v. 21, p. 499-503.
  58. Berkowitz R.B., Roberson S., Zora J. et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc. 1999, v. 20, p. 167-172.
  59. Higgins J., Thompson S., Deeks J., Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J. Health Serv. Res. Policy. 2002, v. 7, p. 51-61.
  60. Yanez A., Rodrigo G.J. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with metaanalysis. Ann. Allergy Asthma Immunol. 2002, v. 89, p. 479-484.
  61. Weiner J.M., Abrahamson M.J., Puy R.M. Intranasal corticosteroids versus H1 receptor antagonists in allergic rhinitis: systemic review of randomized controlled trials. Br. Med. J. 1998, v. 317, p. 1624-1630.
  62. Wihl J.A., Petersen B.N., Petersen L.N. et al. Effect of the nonsedative H1-receptor antagonist astemizole in perennial allergic and nonallergic rhinitis. J. Allergy Clin. Immunol. 1985, v. 75, p. 720-727.
  63. Pullerits T. , Praks L., Ristioja V., Lotvall J. Comparison of nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2002, v. 109, p. 949-955.
  64. Sussman G., Danzig M., Gates D. Total ocular symptom scores in patients with seasonal allergic rhinitis are reduced with mometasone furoate nasal spray. J. Allergy Clin. Immunol. 2007, v. 119, p. S61 [Abstract].
  65. Cohen J. Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
  66. Sterne J.A.C., Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J. Clin. Epidemiol. 2001, v. 54, p. 1046-1055.
  67. Laczo R.M., Sackett P.R., Bobko P., Cortina J.M. A comment on sampling error in the standardized mean difference with unequal sample sizes: avoiding potential errors in meta-analytic and primary research. J. Appl. Psychol. 2005, v. 90, p. 758-764.
  68. Berger W.E., Nayak A.S., Staudinger H.W. Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann. Pharmacother. 2005, v. 39, p. 1984-1989.
  69. Camara-Clark O.A., Araujo-Castro A. Searching the Literatura Latino Americana e do Caribe em Cie?ncias da Sauґ de (LILACS) database improves systematic reviews. Int. J. Epidemiol. 2002, v. 31, p. 112-114.
  70. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, v. 315, p. 629-634.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2009



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies